Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Rozanolixizumab: A Subcutaneously Administered, Humanized Monoclonal Antibody - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

March 11, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Mar 11, 2021--

The “Rozanolixizumab - Emerging Insight and Market Forecast - 2030” report has been added to ResearchAndMarkets.com’s offering.

Rozanolixizumab is a subcutaneously administered, humanized monoclonal antibody that specifically binds, with high affinity, to human FcRn (Fc receptor). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. Currently, the drug is under phase 2 of clinical trials for the treatment of Chronic Inflammatory Demyelinating Syndrome.


“Rozanolixizumab - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Inflammatory Demyelinating Syndrome in 7 Major Markets. A detailed picture of the Rozanolixizumab in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Rozanolixizumab Analytical Perspective

In-depth Rozanolixizumab Market Assessment

This report provides a detailed market assessment of Rozanolixizumab in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

Rozanolixizumab Clinical Assessment

The report provides the clinical trials information of Rozanolixizumab covering trial interventions, trial conditions, trial status, start and completion dates.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Rozanolixizumab.
  • The report contains forecasted sales for Rozanolixizumab till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Chronic Inflammatory Demyelinating Syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of Rozanolixizumab.


Report Highlights

  • In the coming years, the market scenario for Chronic Inflammatory Demyelinating Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Rozanolixizumab dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Inflammatory Demyelinating Syndrome are giving market competition to Rozanolixizumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Rozanolixizumab.
  • This in-depth analysis of the forecasted sales data of Rozanolixizumab from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Rozanolixizumab.

Key Questions Answered

  • Which company is developing Rozanolixizumab along with the phase of the clinical study?
  • What is the technology utilized in the development of Rozanolixizumab?
  • What is the product type, route of administration and mechanism of action of Rozanolixizumab?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Rozanolixizumab development?
  • What are the key designations that have been granted to Rozanolixizumab?
  • What is the forecasted market scenario of Rozanolixizumab?
  • What is the history of Rozanolixizumab and what is its future?
  • What is the forecasted sales of Rozanolixizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to Rozanolixizumab?
  • Which are the late-stage emerging therapies under development for the treatment of the Chronic inflammatory demyelinating Syndrome?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ap3n6j

View source version on businesswire.com:https://www.businesswire.com/news/home/20210311005753/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 03/11/2021 11:17 AM/DISC: 03/11/2021 11:17 AM